Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Consolidation in Older Patients With Primary CNS Lymphoma
NCT04022980Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2020
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Dose-Limiting Toxicities and Progression-Free Survival at 2 years. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04022980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022980.